Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

iAds

Financiado

Intelligent design of adenovirus vectors (iAds)

Advanced therapies, and in particular gene therapies, hold great potential for treating diseases for which few options exist. Efficient gene transfer is inherently and intransigently linked to vector efficacy. Partially due to the... ver más

30/04/2027

CNRS

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 8 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-12-20

HORIZON-EIC-2022-PATHFINDEROPEN-01-01: EIC Pathfinder Open 2022 Scope:You should apply to this call if you are looking for support from EIC Pathfinder Open to reali...

I+D

Cerrada hace 2 años

0% 100% 100%

8 Participantes

CNRS

1.43M€ | Lider

INSERM

166.72K€ | Participante

UNIVERSITE DE MONTPELLIER

51.25K€ | Participante

CSIC

645.12K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

BFU2013-41249-P ESTRUCTURA DE ADENOVIRUS DE ESPECIES Y GENEROS POCO CARACTER... 121K€ Cerrado

PTQ-09-02-01959 MEJORA DE LOS MÉTODOS DE PRODUCCIÓN DE VECTORES ADENOVIRALES... 24K€ Cerrado

SAF2012-39504 MECANISMOS DE ESTABILIZACION Y CONTROL DE LA EXPRESION GENIC... 94K€ Cerrado

RTI2018-097730-B-I00 EXPRESION GENERALIZADA DE TRANSGENES EN INTERNEURONAS INHIBI... 121K€ Cerrado

PTQ-08-01-06701 Desarrollo de nuevos vectores de expresión basados en baculo... 75K€ Cerrado

JCI-2011-09179 El principal objetivo de nuestro laboratorio es el desarroll... 96K€ Cerrado

Duración del proyecto: 52 meses Fecha Inicio: 2022-12-20
Fecha Fin: 2027-04-30

Líder del proyecto

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Descripción del proyecto Advanced therapies, and in particular gene therapies, hold great potential for treating diseases for which few options exist. Efficient gene transfer is inherently and intransigently linked to vector efficacy. Partially due to the lack of suitable delivery systems for particular applications, the success of too many gene therapies is limited. Over the last two decades, immense progress has been made in the development of viral vectors. Importantly, this progress has also identified vector characteristics and biological factors that decrease efficacy. While limited efficacy is relevant for all vector platforms, it is more pressing in the case of adenoviruses because they have so much potential. In some cases, host responses and imperfect targeting have stunted adenovirus vector development for therapies that require long-term transgene expression. Our multi-faceted consortium proposes an innovative approach to overcome these limitations and to construct a pathway for developing improved vectors for clinical gene transfer. By synergising French, Dutch, British, Spanish and Swedish expertise in structural biology, receptor engagement, neurobiology, cardiobiology, and bioprocessing, we will create in silico designed intelligent adenovirus vectors (iAds). Our disruptive concept abandons the classical approach of developing vectors from naturally occurring adenoviruses. Instead, a proprietorial adenovirus type will be serially stripped of unwanted elements to create a bank of iAds, which will then be engineered for heart- and brain-specific targeting. Our consortium blends academic ingenuity and SME/pharma manufacturing that will allow seamless clinical translation. With the support of the EIC Programme, our ground-breaking approach should revolutionise gene transfer and generate solutions in areas of unmet medical need via a platform that exploits the full potential of viral vectors.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores